文献速递肿瘤 PET/CT甲状腺核医学

使用新型放射性示踪剂18F-4FMFES的PET改善雌激素受体阳性乳腺癌患者的雌激素受体评估:一项正在进行的II期临床试验

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.
PubMed 文献 · J Nucl Med · 2017-08-10

这项II期临床试验在31例雌激素受体阳性乳腺癌患者中比较了新型雌激素受体PET示踪剂18F-4FMFES与18F-FES的成像诊断潜力。结果显示18F-4FMFES代谢稳定性更高、非特异性组织摄取更低、肿瘤对比度更好,并比18F-FES多识别出9个病灶。

要点

  • 18F-4FMFES注射后60分钟血液代谢稳定性较18F-FES提高2.5倍。
  • 18F-4FMFES在非特异性组织中摄取更低,血池活性较18F-FES降低4倍。
  • 18F-4FMFES比18F-FES多识别出9个病灶,图像质量明显改善。

核心结论

  • 在雌激素受体阳性乳腺癌患者中,18F-4FMFES PET较18F-FES PET非特异性信号更低、肿瘤对比度更好,从而提高了诊断信心并减少了假阴性诊断。

研究设计与样本

  • II期临床试验纳入31例雌激素受体阳性乳腺癌患者,其中6例接受了乳房切除术或腋窝淋巴结清扫。
  • 每例患者在一周内按随机顺序先后进行18F-FES和18F-4FMFES PET/CT扫描。
  • 注射任一示踪剂后1小时进行头至大腿静态扫描,每个床位采集2分钟。
  • 注射后不同时间点采血,用反相薄层色谱法评估示踪剂代谢。

主要发现

  • 注射后60分钟血液代谢物分析显示18F-4FMFES的代谢稳定性较18F-FES提高2.5倍。
  • 对于大多数病灶,18F-4FMFES PET的SUVmax与18F-FES PET相似,但所有病例的肿瘤对比度均显著改善。
  • 18F-4FMFES在非特异性组织中摄取持续更低,血池活性较18F-FES降低4倍。
  • 18F-4FMFES图像质量明显改善,整体背景活性更低。
  • 18F-4FMFES比18F-FES多成功识别出9个病灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

After encouraging preclinical and human dosimetry results for the novel estrogen receptor (ER) PET radiotracer 4-fluoro-11β-methoxy-16α-18F-fluoroestradiol (18F-4FMFES), a phase II clinical trial was initiated to compare the PET imaging diagnostic potential of 18F-4FMFES with that of 16α-18F-fluoroestradiol (18F-FES) in ER-positive (ER+) breast cancer patients. Methods: Patients diagnosed with ER+ breast cancer (n = 31) were recruited for this study, including 6 who underwent mastectomy or axillary node dissection. For each patient, 18F-FES and 18F-4FMFES PET/CT scans were done sequentially (within a week) and in random order. One hour after injection of either radiotracer, a head-to-thigh static scan with a 2-min acquisition per bed position was obtained. Blood samples were taken at different times after injection to assess each tracer metabolism by reverse-phase thin-layer chromatography. The SUVmean of nonspecific tissues and the SUVmax of the tumor were evaluated for each detected lesion, and tumor-to-nonspecific organ ratios were calculated. Results: Blood metabolite analysis 60 min after injection of the tracer showed a 2.5-fold increase in metabolic stability of 18F-4FMFES over 18F-FES. Although for most foci 18F-4FMFES PET had an SUVmax similar to that of 18F-FES PET, tumor contrast improved substantially in all cases. Lower uptake was consistently observed in nonspecific tissues for 18F-4FMFES, notably a 4-fold decrease in blood-pool activity as compared with 18F-FES. Consequently, image quality was considerably improved using 18F-4FMFES, with lower overall background activity. As a result, 18F-4FMFES successfully identified 9 more lesions than 18F-FES. Conclusion: This phase II study with ER+ breast cancer patients showed that 18F-4FMFES PET achieves a lower nonspecific signal and better tumor contrast than 18F-FES PET, resulting in improved diagnostic confidence and lower false-negative diagnoses.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Paquette M, Lavallée É, Phoenix S, et al. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial. J Nucl Med. 2017. PMID: 28798032. doi:10.2967/jnumed.117.194654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。